Transcatheter Interventions Online 2022 - On Demand
Published: 09 March 2022
Session 1.3: Practical Perspectives in the Context of TAVI
- Session 1.1: Next Level Structural Heart Interventions
- Session 1.2: Live Cases and Discussion
- Symposium: Optimising Outcomes for the TAVI Patient: Key Considerations for First Valve Choice and Implantation Techniques
- Session 1.3: Practical Perspectives in the Context of TAVI
- Session 1.4: Live Cases and Discussions
- BREAKOUT: Current Data and Future Direction in LAAC
- BREAKOUT: Key Considerations to Ensure Long-Term Patients’ Outcomes: When Anatomy, Engineering and Clinical Practice Come Together
Following on from the success of 2021's inaugural edition, Transcatheter Interventions Online 2022 brings together a world-class faculty to provide expert insight and educational learning on the latest developments in interventional management.
Combining expert opinion and discussion, presentations, and live cases from centres on both sides of the Atlantic, TIO 2022 delivers best-in-class learning, supporting the latest in diagnosis, treatment strategies and patient management.
Note, the live version of this session was CME accredited; this on-demand version is not.
Key Learning Objectives
- Describe the practical implications of TAVI in the context of coronary artery disease, atrioventricular valve disease and transcatheter heart valve degeneration
- Select appropriate tools for calcified coronary artery disease, including mechanical circulatory support and invasive imaging techniques
- Understand coronary physiology, novel recanalization and goal-oriented planning for chronic total occlusion
- Evaluate the role of novel oral anticoagulants in transcatheter aortic valve implantation
- Discuss the need for gender-specific trials and renal denervation
- Interventional Cardiologists
- Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
- Interventional Cardiology Nurses
More from this programme
Day One: Structural Heart Disease
Day Two: Coronary Heart Disease: High Risk & Complex PCI
Day Three: Debates and Controversies
Kendra J Grubb
Dr Kendra Grubb is the surgical director of the structural heart and valve center at Emory Healthcare. She is also an associate professor of surgery at Emory University School of Medicine.
Dr Grubb is a champion for women's heart disease and is dedicated to improving the lives of all patients through innovation, collaboration and a patient-centered approach to the treatment of cardiovascular disease.1
After obtaining her BS in Biology from the University of Southern California (1999), Dr Grubb attended the University of Southern California, where she received her a master’s in health administration from the Sol Price School of Public Policy (2001), followed by an MD degree at the Keck School of Medicine (2005).1
She pursued a general surgery residency at the University of Illinois at Chicago between…
Didier Tchétché, (Clinique Pasteur, Toulouse, France) Graduated from the University of Paris V where Dr Tchétché obtained his post-graduate diploma of cardiovascular pathology in 2004. From 2004 to 2005, he completed a 12-month fellowship period in the Hemodynamic and Interventional Cardiology department of Clinique Pasteur in Toulouse and from 2005 to 2007 he was Head Assistant at the intensive care unit of Bichât Hospital in Paris.
In 2008, he joined the interventional cardiovascular group in Clinique Pasteur, Toulouse, and he is currently Head of the Structural programme with an experience of more than 5000 TAVI procedures. His main areas of interest are coronary interventions and valvular heart disease. He has been actively involved in many clinical trials involving new technologies and devices in the field of interventional cardiology.
Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, FSCAI is Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A Weiner Cardiovascular Institute at Mount Sinai School of Medicine.
Prof Mehran is Professor of Medicine, Cardiology and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai in New York. She is also Director of Interventional Cardiovascular Research and Clinical Trials at The Zena and Michael A Weiner Cardiovascular Institute at Mount Sinai Hospital where, over the past 5 years, she has led the development of a globally respected data and clinical coordination centre to support large, multicentre, multinational clinical trials designed to help improve outcomes and quality of life for patients undergoing interventional cardiovascular procedures. In recent years, her work has had a special emphasis on gaining a deeper understanding of anticoagulation and…
David Hildick-Smith is a Professor of Interventional Cardiology and Consultant Cardiologist at the Sussex Cardiac Centre. He is Director of the Cardiac Research, ex-Treasurer of the British Cardiovascular Interventions Society, and has more than 15 years experience of Interventional Cardiology.
Dr Søndergaard is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3).